Alkermes (ALKS) Shares Outstanding (Diluted Average) (2011 - 2023)
Alkermes (ALKS) reported Shares Outstanding (Diluted Average) of $169.7 million for Q4 2023, up 3.66% year-over-year from $163.7 million in Q4 2022, and up 2.81% quarter-over-quarter from $165.1 million in Q1 2023.
Alkermes (ALKS) Shares Outstanding (Diluted Average) (2011 - 2023) Analysis & Trends
Alkermes (ALKS) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $169.7 million in Q4 2023.
- Shares Outstanding (Diluted Average) for Q4 2023 came in at $169.7 million, up 3.66% year-over-year; the trailing twelve-month figure through Dec 2023 was $169.7 million (up 3.66% YoY), and the FY2023 annual result was $169.7 million, up 3.66% from the prior year.
- Shares Outstanding (Diluted Average) grew to $169.7 million in Q4 2023 per ALKS's latest filing, from $165.1 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $169.7 million in Q4 2023 and troughed at $158.8 million in Q4 2020.
- A 4-year average of $163.6 million and a median of $163.6 million in 2022 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2021 and 2022: Shares Outstanding (Diluted Average) climbed 3.75% in 2021, then decreased 0.61% in 2022.
- A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $158.8 million in 2020, then gained by 3.75% to $164.8 million in 2021, then fell by 0.61% to $163.7 million in 2022, then advanced by 3.66% to $169.7 million in 2023.
- Business Quant data shows ALKS's Shares Outstanding (Diluted Average) at $169.7 million in Q4 2023, $165.1 million in Q1 2023, and $163.7 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 103.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 228.36 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 101.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 169.73 Mn |
| Mar 31, 2023 | 165.09 Mn |
| Dec 31, 2022 | 163.74 Mn |
| Sep 30, 2022 | 163.54 Mn |
| Mar 31, 2022 | 162.48 Mn |
| Dec 31, 2021 | 164.75 Mn |
| Sep 30, 2021 | 160.64 Mn |
| Dec 31, 2020 | 158.80 Mn |
| Jun 30, 2014 | 144.14 Mn |
| Mar 31, 2014 | 143.36 Mn |
| Sep 30, 2013 | 135.36 Mn |
| Jun 30, 2013 | 141.82 Mn |
| Mar 31, 2013 | 139.68 Mn |
| Sep 30, 2012 | 135.59 Mn |
| Mar 31, 2012 | 114.70 Mn |
| Sep 30, 2011 | 102.47 Mn |
| Mar 31, 2011 | 95.61 Mn |